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Abstract
Background: IL4/IL4RA pathway plays an important role in atopy and asthma. Different polymorphisms
in IL4 and IL4RA genes have been described. Particularly, -33C>TIL4 and 576Q>RIL4RA SNPs have been
independently associated to atopy and asthma. The purpose of this study was to analyse these
polymorphisms in a population of patients with a well-characterized asthma phenotype.
Methods: A total of 212 unrelated Caucasian individuals, 133 patients with asthma and 79 healthy subjects
without symptoms or history of asthma or atopy and with negative skin prick tests were recruited. Lung
function was measured by spirometry and asthma was specialist physician-diagnosed according to the ATS
(American Thoracic Society) criteria and classified following the GINA (Global Initiative for Asthma)
guidelines. Skin prick tests were performed according to EAACI recommendations. -33C>TIL4 was
studied with TaqMan assay and 576Q>RIL4RA by PCR-RFLP technique. Hardy-Weinberg equilibrium was
analysed in all groups. Dichotomous variables were analysed using χ2, Fisher exact test, Monte Carlo
simulation test and odds ratio test. To model the effects of multiple covariates logistic regression was used.
Results: No statistically significant differences between the group of patients with asthma and the controls
were found when the allele and genotype distribution of -33C>TIL4 and 576Q>RIL4RA polymorphisms
were compared. However, the T allele of the -33C>TIL4 SNP was more frequent in patients with
persistent asthma. Multivariate analysis adjusted for age and sex confirmed that carriers of allele T had an
increased risk of persistent asthma (OR:2.77, 95%CI:1.18–6.49; p = 0.019). Analysis of combination of
polymorphisms showed that patients carrying both the T allele of -33C>TIL4 and the A allele of
576Q>RIL4RA had an increased risk of asthma. This association was particularly observed in persistent
asthma [Fisher's p value = 0.0021, Monte Carlo p value (after 104 simulations) = 0.0016, OR:3.39; 95%
CI:1.50–7.66].
Conclusion: Our results show a trend of association between the genetic combination of the T allele of
-33C>TIL4 and the A allele of 576Q>RIL4RA with asthma. This genetic variant was more frequently
observed in patients with persistent asthma. As long as this study was performed in a small population,
further studies in other populations are needed to confirm these results.
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IL-4 is a Th2 cytokine that plays an essential role in IgE
regulation. It triggers isotype switching from IgM to IgE,
induces differentiation to Th2 phenotype on T cells and
plays a critical role in the induction and maintenance of
allergy.IL4 gene has been mapped to chromosome 5q31
where asthma and atopy have also been linked [1-3]. Evi-
dence that IL4 polymorphisms are associated with total
IgE levels and potentially with asthma and other allergy
related phenotypes has been provided, although ethnical
differences have been reported [4]. Specifically, the pro-
moter region of IL4 has been associated with asthma phe-
notype [5] and a -33C>T polymorphism has been
reported in this region [6]. An association between this
polymorphism and asthma or atopy has been found,
although this relation is still controversial [4,7-10]. IL-4
acts through the IL-4 receptor (IL-4R) that consists of two
subunits, the α chain (IL-4Rα) and the γ chain (γc)
[11,12]. IL-4Rα is a component of both the IL-4 and the
IL-13 receptor complexes [13]. The IL4RA gene is located
on chromosome 16p (16p12.1) [14], a region reported in
linkage with atopy in different populations [15,16]. Sev-
eral single-nucleotide polymorphisms (SNPs) have been
identified in the coding region of the IL4RA gene, many of
them resulting in aminoacid substitutions [17,18]. One of
these polymorphisms, 576Q>R, consists of an A-to-G
transition at nucleotide 1902, causing a change from
glutamine to arginine at codon 576 (Q576R) in the cyto-
plasmic domain of the IL-4Rα. It has been reported that B-
lymphocytes isolated from allergic patients bearing the
576Q>R mutation have an enhanced CD23 induction in
response to IL-4 [19]. However, this result has not been
confirmed by other authors [20]. Association of the
576Q>R polymorphism with the atopic phenotype has
been described, but this relationship is still controversial
[19,21-31]. Due to the central role of the IL-4/IL-4RA
pathway in atopy and the scarce information about com-
binations of both genes in South European populations,
we have analysed the -33C>T polymorphism of IL4 gene
and the 576Q>R polymorphism of IL4RA gene in a Span-




We studied 212 unrelated Caucasian individuals, 133
patients and 79 controls, recruited from the outpatient
Allergy Department of the University Hospital of Sala-
manca. The study was performed following the recom-
mendations of the Ethical Committee of the University
Hospital of Salamanca and informed written consent was
obtained from each patient. Individuals who met all the
following criteria were selected as controls: (i) no symp-
toms or history of asthma or other pulmonary diseases;
(ii) no symptoms or history of atopy; (iii) negative skin
prick tests to a battery of common aeroallergens (<1 mm
wheal greater than saline) and (iv) absence of first-degree
relatives with a history of asthma or atopy. Asthmatic
patients were recruited if they had specialist physician-
diagnosed asthma with the following characteristics: (i) at
least two symptoms consistent with asthma (cough,
wheeze and dyspnoea); (ii) either a positive bronchial
hyperresponsiveness or a positive bronchodilator test
defined as a ≥ 15% increase in baseline FEV1 after bron-
chodilator use; (iii) absence of other pulmonary disor-
ders. Lung function was measured by spirometry
according to ATS (American Thoracic Society) standards
and severity of asthma was classified following GINA
(Global Initiative for Asthma) guidelines. Asthma
patients were grouped into intermittent and persistent by
the clinical severity and into allergic and non allergic
asthma by the clinical etiology.
Skin prick tests were performed according to EAACI rec-
ommendations with a battery of common aeroallergens
that included D pteronisynuss, D farinae, L destructor, T
putrescentiae, A siro, G domesticus, E maynei, mix of grasses,
mix of trees, P judaica, C album, A vulgaris, P lanceolata, O
europaea, A alternata, C herbarum, P notatum, A fumigatus,
dog, cat, hamster, horse and rabbit dander and cockroach
(ALK-Abelló, Madrid, Spain). Saline was used as negative
control and histamine 10 mg/ml was used as positive con-
trol. Antihistamines were discontinued before skin testing
according to published guidelines. Skin tests were consid-
erer positive if at least one allergen elicited a wheal reac-
tion of more than 3 mm of diameter after subtraction of
the negative control. Patients were considered atopic if at
least they had one positive skin test result. Total serum IgE
was measured by a fluoroenzymeimmunoassay (Pharma-
cia Cap System®; Pharmacia, Uppsala, Sweden), according
to the manufacturer's instructions.
Genotyping analysis
After purification from peripheral blood leukocytes, DNA
was amplified by polymerase chain reaction (PCR). Gen-
otyping of -33C>TIL4 SNP was performed using a Taq-
Man assay in the ABI 7700 sequence detector and the
allelic discrimination software Sequence Detector v1.7
according to the manufacturer's recommendations
(Applied Biosystems). Primers and probes were obtained
by means of the Assays-by-Demand SNP genotyping serv-
ice of Applied Biosystems, Assay ID: C 16176215. Geno-
typing of the 576Q>RIL4RA polymorphism was
performed according to a previously published assay [28].
Two oligonucleotides were used to amplify the polymor-
phic region of IL4RA: 5'-CCCCCACCACCAGTGGCTACC-
3' and 5'-CCAGGAATGAGGTCTTGGAA-3' [24]. PCR reac-
tions were carried out in a total volume of 25 µL, contain-
ing 50 ng of DNA and 12.5 µL of PCR Master Mix 2 ×
(Promega, Madison, Wisconsin). Amplification was per-Page 2 of 7
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min followed by 30 cycles of denaturation at 94°C for 1
min, primer annealing at 55°C for 1 min, and extension
at 72° for 1 min. A final extension was carried out at 72°
for 10 min. A blank amplification tube was always run to
check for the presence of contamination. Strict rules were
taken to avoid contamination. PCR reactions were pre-
pared on a laminar flow hood and PCR products were
examined in a different room. PCR products were digested
for 4 h at 37°C with 1 U of MspI (New England Biolab,
Boston, Massachusetts) restriction enzyme. After enzy-
matic digestion of the amplified fragments, the samples
were analyzed by electrophoresis in 3% nusieve agarose
gel. Control and patients were not genotyped in separated
batched and the analysis was performed blindly with
respect to case-control status.
Statistical analysis
For case-control studies, the allele and genotype frequen-
cies in patients with asthma were compared to a control
non-asthmatic population. All the groups were tested for
Hardy-Weinberg equilibrium using χ2 analyses. The
dichotomous variables were analysed using χ2, Fisher
exact test, Monte Carlo simulation test (after 104 itera-
tions) and odds ratio test. IgE levels were transformed to
log10 values to produce a normal distribution for statisti-
cal analysis and analysed by ANOVA. To model the effects
of multiple covariates on the dichotomous and continu-
ous variables, logistic regression was used. In multivariate
analysis, sex and age were included as potential covariates.
A p-value less than 0.05 was considered statistically signif-
icant. Bonferroni correction was applied when appropri-
ate. Case-control studies were also undertaken using
combination of polymorphisms. Frequencies of combina-
tions were estimated individually in controls and in sam-
ples to give the results of both single combinations and
global data. For management of data, SHEsis software




Characteristics of patients and controls are shown in Table
1. Genotype and allele frequencies are shown in Table 2.
The -33TIL4 allele was found at a frequency of 0.15 in
patients with asthma versus 0.09 in controls. No statisti-
cally significant differences between patients with asthma
and controls were found. However, we observed an
increase of the -33T IL4 allele in patients with persistent
asthma compared to controls [Fisher's p value = 0.014,
Monte Carlo p value (after 104 simulations) = 0.019].
Multivariate analysis of the genotypes adjusted for age
and sex confirmed a trend of association of -33C>TIL4
polymorphism with an increased risk of persistent asthma
(OR: 2.77, 95% CI: 1.18–6.49; p = 0.019). No differences
were found in the group of subjects suffering allergic
asthma compared to controls. Analysis of the total IgE lev-
els failed to reveal any significant difference (p = 0.22),
even when separate analysis for each gender was per-
formed (data not shown).
576Q>RIL4RA SNP
576RIL4RA arginine allele (G) was found at a frequency of
0.16 in patients with asthma versus 0.21 in healthy sub-
jects (Table 2). We did not observe differences between
patients and controls in allele or genotype frequencies. No
association was detected with asthma phenotype or with
asthma severity (Table 2). 576Q>RIL4RA polymorphism
was not related to total serum IgE levels in our population
(p = 0.35).
Gene-gene interaction analysis
We did not detect differences in the global distribution of
-33C>TIL4 / 576Q>RIL4RA combinations between the
group of patients with asthma and the group of controls
(Monte Carlo p value = 0.074) (Table 3). However,
patients who were carriers of both the T allele of -
33C>TIL4 and the A allele of IL4RA had an increased risk
of asthma [Fisher's p value = 0.017, Monte Carlo p value
Table 1: Demographic characteristics of patients
Characteristic Controls Patients P value
No. of subjects 79 133
Age ± SD (y) 40 ± 18 32 ± 17 0.001
Sex (No.)
Male 28 56 0.38
Female 51 77
Log IgE ± SD 1.36 ± 0.67 2.18 ± 0.71 <0.001
SD: standard deviation
y: yearsPage 3 of 7
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1.18–5.66].
Slight differences in the global distribution of genetic var-
iants were detected between the group of patients with
atopy and the group of controls [Fisher's p value = 0.05,
Monte Carlo p value (after 104 simulations) = 0.045].
Patients who were carriers of both the T allele of -
33C>TIL4 and the A allele of IL4RA had an increased risk
of atopy [Fisher's p value = 0.013, Monte Carlo p value
(after 104 simulations = 0.016, odds ratio, 2.64; 95 % CI,
1.93–5.87] (Table 3).
Differences in genetic variants distribution were also
observed in the group of patients with allergic asthma
compared to controls, although these differences did not
reach statistical signification globally considered (Fisher p
value = 0.053, Monte Carlo p value = 0.053). Again the
combination of T and A alleles showed a trend of associa-
tion [Fisher's p value = 0.016, Monte Carlo p value =
0.017, odds ratio, 2.62; 95 % CI, 1.17–5.90] (Table 3).
When we compared patients with persistent asthma to
controls, significant differences in the global combination
distribution were observed (Fisher's p value = 0.018,
Monte Carlo p value = 0.017). Patients who carried both
the T allele of -33C>TIL4 and the A allele of IL4RA had an
increased risk of persistent asthma [Fisher's p value =
0.0021, Monte Carlo p value = 0.0016, odds ratio, 3.39;
95 % CI, 1.50–7.66] (Table 3).
Discussion
-33C>TIL4 SNP
We studied -33C>TIL4 and 576Q>RIL4RA polymor-
phisms in a well-characterized Spanish population of
patients with asthma and in a healthy control population.
Controls were older than patients allowing a longer
period for asthma diagnosis to be made. When we ana-
lysed the -33C>T polymorphism independently, we did
not detect significant differences in allele or genotype fre-
quencies between the group of patients and the group of
controls. Nevertheless, we observed a higher incidence of
the T allele of -33IL4 in the group of patients with asthma
(Table 2).
An association between -33C>TIL4 polymorphism and
asthma or atopy has been previously reported, although
this association is controversial [4,7-9]. In previous stud-
ies, no statistically significant association between -
33C>TIL4 polymorphism and atopic dermatitis, bron-
chial hyperresponsiveness, atopic rhinitis and skin prick
test reactivity was found [7,9]. However, a significant
trend for an association between serum IgE levels and this
SNP has been detected in children with positive skin prick
tests, independent of asthma status [7].
As shown in table 2, we detected that the allele -33TIL4 is
more frequent in patients with allergic asthma, although,
we did not detect an association between this polymor-
phism and IgE levels.
It has been reported that polymorphisms within the pro-
moter region of IL4 gene seems to correlate with enhanced
IL4 activity [5,33], secondary to modification of IL4 gene
Table 2: Genotype and allele frequencies of -33C>TIL4 and 576Q>RIL4RA SNPs
Phenotype Genotype Allele HWE p value
-33C>T IL4 N Log IgE ± SD CC TC TT C T
Controls 79 1.36 ± 0.67 0.81 0.19 0 0.91 0.09 0.35
Asthma 133 2.18 ± 0.71 0.70 0.29 0.01 0.85 0.15 0.15
Allergic Asthma 99 2.42 ± 0.56 0.69 0.30 0.01 0.84 0.16 0.24
Non-allergic Asthma 34 1.59 ± 0.76 0.74 0.26 0 0.87 0.13 0.37
Intermittent Asthma 54 2.39 ± 0.60 0.79 0.19 0.02 0.89 0.11 0.65
Persistent Asthma 79 2.09 ± 0.76 0.63 0.37* 0 0.82 0.18† 0.05
576Q>R IL4RA AA AG GG A G
Controls 79 1.36 ± 0.67 0.62 0.33 0.05 0.79 0.21 0.82
Asthma 133 2.18 ± 0.71 0.68 0.31 0.01 0.84 0.16 0.10
Allergic Asthma 99 2.42 ± 0.56 0.71 0.29 0 0.85 0.15 0.09
Non Allergic Asthma 34 1.59 ± 0.76 0.59 0.38 0.03 0.78 0.22 0.51
Intermittent asthma 54 2.39 ± 0.60 0.67 0.33 0 0.83 0.17 0.14
Persistent asthma 79 2.09 ± 0.76 0.68 0.30 0.01 0.84 0.16 0.35
HWE: Hardy-Weinberg Equilibrium
* Fisher's p value = 0.013, Monte Carlo p value (after 104 simulations) = 0.019
†Fisher's p value = 0.023, Monte Carlo p value (after 104 simulations) = 0.037Page 4 of 7
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that the T allele may be associated with severity of asthma
[23,34,35]. In our study, a trend of association of -33TIL4
allele with persistent asthma was observed.
576Q>RIL4RA SNP
Analysis of 576Q>RIL4RA polymorphism did not reveal
any association with asthma phenotype. It has been
reported a relationship of the 576Q>RIL4RA SNP with the
atopic phenotype, however this relationship is still con-
troversial [19,21-31,36-38]. In a previous study, we did
not find any association of this polymorphism with atopy
or IgE levels, except in a specific of group of patients with
family history of atopy [28].
Kruse et al [21] associated the R allele with lower total IgE
values, but Hersey et al [19]found an association with
high levels of total IgE. We did not detect any association
with IgE levels. Genetic association studies are often diffi-
cult to interpret due to poor reproducibility in different
populations [39,40]. This may well result, among other
reasons, from the fact that these studies are focused only
on one SNP [18,26,27] and that penetrance of the alleles
may be influence by other factors [19].
Gene-gene interaction analysis
When we analysed both polymorphisms simultaneously,
differences between the group of patients with asthma
and controls were detected. Particularly, patients who
were carriers of both the T allele of -33C>TIL4 and the A
allele of 576Q>RIL4RA had an increased risk of asthma.
Significant differences were observed in the group of
patients with allergic asthma compared to controls. In
addition, patients who carried both the T allele of -
33C>TIL4 and the A allele of 576Q>RIL4RA had an
increased risk of persistent asthma, in our population.
It has been previously suggested that both SNPs may
modify the susceptibility to atopy or atopic asthma, inde-
pendently. The importance of analysis of genetic variants
has been previously illustrated, because the functional sig-
nificance of a given polymorphism may only be evident in
a specific setting of additional SNPs in the same or differ-
ent genes [40]. It has also been pointed out that genetic
association studies need careful classification of pheno-
types, application of quality control in the performance of
laboratory procedures and very stringent significant levels
to assure reproducibility [20,39]., although it also may
indicate true heterogeneity in gene-disease associations.
We describe for the first time a specific genetic combina-
tion of IL4/IL4RA polymorphisms that shows a trend of
association to persistent asthma in a South European pop-
ulation. As long as this study was performed in a small
population, further studies in other populations are
needed to confirm these results.
Conclusion
We show a trend of association between -33C>TIL4 and
576Q>RIL4RA polymorphisms and asthma phenotype in
a Spanish population. Patients who carried both the T
allele of -33C>TIL4 and the A allele of 576Q>RIL4RA
showed an increased risk of allergic asthma. In the popu-
lation included in our study this combination was
observed more frequently in patients with persistent
asthma.
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